Inden for dette dosisinterval er der hos raske frivillige personer ikke observeret nogen statistisk signifikant hæmning af COX- 1 (vurderet som ex vivo hæmning af tromboxan B2 (TxB2) dannelse).
No statistically significant inhibition of COX-1 (assessed as ex vivo inhibition of thromboxane B2 [TxB2] formation) was observed in this dose range in healthy volunteers.